Skip to content

Xenetic Biosciences (XBIO) Stock Rallies On $12.5m Private Placement

Xenetic Biosciences (NASDAQ: XBIO) shares are rallying premarket after it announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor to purchase 4.6 million shares of its common stock.

The investor will purchase the stock for $2.70 per share in a private placement.

Xenetic has also agreed to issue to the investor warrants to purchase up to 4.6 million shares of common stock at an exercise price of $3.30. They will be immediately exercisable and will expire in three and a half years.

The gross proceeds are expected to be approximately $12.5 million, with the potential gross proceeds from the exercise of the warrants, if fully exercised, roughly $15.3 million.

The company said it plans t use the proceeds for general working capital purposes.

Xenetic’s share price has climbed 25% to $3.15 following the announcement after closing Friday’s session up 35.4% to $2.52.

Should You Invest in Xenetic Biosciences Shares?

One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now

Sam Boughedda
Sam Boughedda
Team Member

Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples. 

Stay ahead of the markets

Sign up to our free Morning Markets email, every weekday before the open.